IBDEI10H ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,16451,0)
;;=I09.89^^61^774^17
;;^UTILITY(U,$J,358.3,16451,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16451,1,3,0)
;;=3^Rheumatic Heart Diseases NEC
;;^UTILITY(U,$J,358.3,16451,1,4,0)
;;=4^I09.89
;;^UTILITY(U,$J,358.3,16451,2)
;;=^5007060
;;^UTILITY(U,$J,358.3,16452,0)
;;=I47.1^^61^774^24
;;^UTILITY(U,$J,358.3,16452,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16452,1,3,0)
;;=3^Supraventricular Tachycardia
;;^UTILITY(U,$J,358.3,16452,1,4,0)
;;=4^I47.1
;;^UTILITY(U,$J,358.3,16452,2)
;;=^5007223
;;^UTILITY(U,$J,358.3,16453,0)
;;=I48.0^^61^774^15
;;^UTILITY(U,$J,358.3,16453,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16453,1,3,0)
;;=3^Paroxysmal Atrial Fibrillation
;;^UTILITY(U,$J,358.3,16453,1,4,0)
;;=4^I48.0
;;^UTILITY(U,$J,358.3,16453,2)
;;=^90473
;;^UTILITY(U,$J,358.3,16454,0)
;;=I49.5^^61^774^23
;;^UTILITY(U,$J,358.3,16454,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16454,1,3,0)
;;=3^Sick Sinus Syndrome
;;^UTILITY(U,$J,358.3,16454,1,4,0)
;;=4^I49.5
;;^UTILITY(U,$J,358.3,16454,2)
;;=^110404
;;^UTILITY(U,$J,358.3,16455,0)
;;=I49.8^^61^774^3
;;^UTILITY(U,$J,358.3,16455,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16455,1,3,0)
;;=3^Cardiac Arrhythmias
;;^UTILITY(U,$J,358.3,16455,1,4,0)
;;=4^I49.8
;;^UTILITY(U,$J,358.3,16455,2)
;;=^5007236
;;^UTILITY(U,$J,358.3,16456,0)
;;=I49.9^^61^774^2
;;^UTILITY(U,$J,358.3,16456,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16456,1,3,0)
;;=3^Cardiac Arrhythmia,Unspec
;;^UTILITY(U,$J,358.3,16456,1,4,0)
;;=4^I49.9
;;^UTILITY(U,$J,358.3,16456,2)
;;=^5007237
;;^UTILITY(U,$J,358.3,16457,0)
;;=R00.1^^61^774^1
;;^UTILITY(U,$J,358.3,16457,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16457,1,3,0)
;;=3^Bradycardia,Unspec
;;^UTILITY(U,$J,358.3,16457,1,4,0)
;;=4^R00.1
;;^UTILITY(U,$J,358.3,16457,2)
;;=^5019164
;;^UTILITY(U,$J,358.3,16458,0)
;;=I34.1^^61^774^14
;;^UTILITY(U,$J,358.3,16458,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16458,1,3,0)
;;=3^Nonrheumatic Mitral Valve Prolapse
;;^UTILITY(U,$J,358.3,16458,1,4,0)
;;=4^I34.1
;;^UTILITY(U,$J,358.3,16458,2)
;;=^5007170
;;^UTILITY(U,$J,358.3,16459,0)
;;=D68.4^^61^775^1
;;^UTILITY(U,$J,358.3,16459,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16459,1,3,0)
;;=3^Acquired Coagulation Factor Deficiency
;;^UTILITY(U,$J,358.3,16459,1,4,0)
;;=4^D68.4
;;^UTILITY(U,$J,358.3,16459,2)
;;=^2235
;;^UTILITY(U,$J,358.3,16460,0)
;;=D59.9^^61^775^2
;;^UTILITY(U,$J,358.3,16460,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16460,1,3,0)
;;=3^Acquired Hemolytic Anemia,Unspec
;;^UTILITY(U,$J,358.3,16460,1,4,0)
;;=4^D59.9
;;^UTILITY(U,$J,358.3,16460,2)
;;=^5002330
;;^UTILITY(U,$J,358.3,16461,0)
;;=C91.00^^61^775^5
;;^UTILITY(U,$J,358.3,16461,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16461,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,16461,1,4,0)
;;=4^C91.00
;;^UTILITY(U,$J,358.3,16461,2)
;;=^5001762
;;^UTILITY(U,$J,358.3,16462,0)
;;=C91.01^^61^775^4
;;^UTILITY(U,$J,358.3,16462,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16462,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,16462,1,4,0)
;;=4^C91.01
;;^UTILITY(U,$J,358.3,16462,2)
;;=^5001763
;;^UTILITY(U,$J,358.3,16463,0)
;;=C92.01^^61^775^7
;;^UTILITY(U,$J,358.3,16463,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16463,1,3,0)
;;=3^Acute Myeloblastic Leukemia,In Remission
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI10H 3812 printed Oct 16, 2024@18:00:10 Page 2
IBDEI10H ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,16451,0)
+2 ;;=I09.89^^61^774^17
+3 ;;^UTILITY(U,$J,358.3,16451,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,16451,1,3,0)
+6 ;;=3^Rheumatic Heart Diseases NEC
+7 ;;^UTILITY(U,$J,358.3,16451,1,4,0)
+8 ;;=4^I09.89
+9 ;;^UTILITY(U,$J,358.3,16451,2)
+10 ;;=^5007060
+11 ;;^UTILITY(U,$J,358.3,16452,0)
+12 ;;=I47.1^^61^774^24
+13 ;;^UTILITY(U,$J,358.3,16452,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,16452,1,3,0)
+16 ;;=3^Supraventricular Tachycardia
+17 ;;^UTILITY(U,$J,358.3,16452,1,4,0)
+18 ;;=4^I47.1
+19 ;;^UTILITY(U,$J,358.3,16452,2)
+20 ;;=^5007223
+21 ;;^UTILITY(U,$J,358.3,16453,0)
+22 ;;=I48.0^^61^774^15
+23 ;;^UTILITY(U,$J,358.3,16453,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,16453,1,3,0)
+26 ;;=3^Paroxysmal Atrial Fibrillation
+27 ;;^UTILITY(U,$J,358.3,16453,1,4,0)
+28 ;;=4^I48.0
+29 ;;^UTILITY(U,$J,358.3,16453,2)
+30 ;;=^90473
+31 ;;^UTILITY(U,$J,358.3,16454,0)
+32 ;;=I49.5^^61^774^23
+33 ;;^UTILITY(U,$J,358.3,16454,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,16454,1,3,0)
+36 ;;=3^Sick Sinus Syndrome
+37 ;;^UTILITY(U,$J,358.3,16454,1,4,0)
+38 ;;=4^I49.5
+39 ;;^UTILITY(U,$J,358.3,16454,2)
+40 ;;=^110404
+41 ;;^UTILITY(U,$J,358.3,16455,0)
+42 ;;=I49.8^^61^774^3
+43 ;;^UTILITY(U,$J,358.3,16455,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,16455,1,3,0)
+46 ;;=3^Cardiac Arrhythmias
+47 ;;^UTILITY(U,$J,358.3,16455,1,4,0)
+48 ;;=4^I49.8
+49 ;;^UTILITY(U,$J,358.3,16455,2)
+50 ;;=^5007236
+51 ;;^UTILITY(U,$J,358.3,16456,0)
+52 ;;=I49.9^^61^774^2
+53 ;;^UTILITY(U,$J,358.3,16456,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,16456,1,3,0)
+56 ;;=3^Cardiac Arrhythmia,Unspec
+57 ;;^UTILITY(U,$J,358.3,16456,1,4,0)
+58 ;;=4^I49.9
+59 ;;^UTILITY(U,$J,358.3,16456,2)
+60 ;;=^5007237
+61 ;;^UTILITY(U,$J,358.3,16457,0)
+62 ;;=R00.1^^61^774^1
+63 ;;^UTILITY(U,$J,358.3,16457,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,16457,1,3,0)
+66 ;;=3^Bradycardia,Unspec
+67 ;;^UTILITY(U,$J,358.3,16457,1,4,0)
+68 ;;=4^R00.1
+69 ;;^UTILITY(U,$J,358.3,16457,2)
+70 ;;=^5019164
+71 ;;^UTILITY(U,$J,358.3,16458,0)
+72 ;;=I34.1^^61^774^14
+73 ;;^UTILITY(U,$J,358.3,16458,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,16458,1,3,0)
+76 ;;=3^Nonrheumatic Mitral Valve Prolapse
+77 ;;^UTILITY(U,$J,358.3,16458,1,4,0)
+78 ;;=4^I34.1
+79 ;;^UTILITY(U,$J,358.3,16458,2)
+80 ;;=^5007170
+81 ;;^UTILITY(U,$J,358.3,16459,0)
+82 ;;=D68.4^^61^775^1
+83 ;;^UTILITY(U,$J,358.3,16459,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,16459,1,3,0)
+86 ;;=3^Acquired Coagulation Factor Deficiency
+87 ;;^UTILITY(U,$J,358.3,16459,1,4,0)
+88 ;;=4^D68.4
+89 ;;^UTILITY(U,$J,358.3,16459,2)
+90 ;;=^2235
+91 ;;^UTILITY(U,$J,358.3,16460,0)
+92 ;;=D59.9^^61^775^2
+93 ;;^UTILITY(U,$J,358.3,16460,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,16460,1,3,0)
+96 ;;=3^Acquired Hemolytic Anemia,Unspec
+97 ;;^UTILITY(U,$J,358.3,16460,1,4,0)
+98 ;;=4^D59.9
+99 ;;^UTILITY(U,$J,358.3,16460,2)
+100 ;;=^5002330
+101 ;;^UTILITY(U,$J,358.3,16461,0)
+102 ;;=C91.00^^61^775^5
+103 ;;^UTILITY(U,$J,358.3,16461,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,16461,1,3,0)
+106 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
+107 ;;^UTILITY(U,$J,358.3,16461,1,4,0)
+108 ;;=4^C91.00
+109 ;;^UTILITY(U,$J,358.3,16461,2)
+110 ;;=^5001762
+111 ;;^UTILITY(U,$J,358.3,16462,0)
+112 ;;=C91.01^^61^775^4
+113 ;;^UTILITY(U,$J,358.3,16462,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,16462,1,3,0)
+116 ;;=3^Acute Lymphoblastic Leukemia,In Remission
+117 ;;^UTILITY(U,$J,358.3,16462,1,4,0)
+118 ;;=4^C91.01
+119 ;;^UTILITY(U,$J,358.3,16462,2)
+120 ;;=^5001763
+121 ;;^UTILITY(U,$J,358.3,16463,0)
+122 ;;=C92.01^^61^775^7
+123 ;;^UTILITY(U,$J,358.3,16463,1,0)
+124 ;;=^358.31IA^4^2
+125 ;;^UTILITY(U,$J,358.3,16463,1,3,0)
+126 ;;=3^Acute Myeloblastic Leukemia,In Remission
